Frances Boyle

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Fátima Cardoso, Shani Paluch–Shimon, Elżbieta Senkus et al. · Annals of Oncology · 2020 · 1.4K citations · Full text

Medicine, Oncology, Surgery +13

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

Halle C. F. Moore, Joseph M. Unger, Kelly‐Anne Phillips et al. · New England Journal of Medicine · 2015 · 542 citations · Full text

Medicine, Gynecology, Oncology +16

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

Evandro de Azambuja, Andrew Holmes, Martine Piccart et al. · The Lancet Oncology · 2014 · 455 citations

Medicine, Oncology, Pharmacology +15

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Martine Piccart, Eileen Holmes, José Baselga et al. · Journal of Clinical Oncology · 2015 · 374 citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

Priya Rastogi, Joyce O’Shaughnessy, Miguel Martín et al. · Journal of Clinical Oncology · 2024 · 204 citations · Full text

Medicine, Oncology, Pharmacology +15